title: Reply to Phillips, Morris, and Walker.
authors.affiliation: Harvard University, Boston, Massachusetts.
authors.forename: Scott
authors.initials: S
authors.lastname: Evans
authors.affiliation: National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
authors.forename: Dean
authors.initials: D
authors.lastname: Follmann
authors.affiliation: Massachusetts General Hospital, Boston.
authors.forename: David
authors.initials: D
authors.lastname: Schoenfeld
authors.affiliation: Duke University, Durham, North Carolina.
authors.forename: Vance G
authors.initials: VG
authors.lastname: Fowler
authors.affiliation: University of California, San Francisco.
authors.forename: Henry F
authors.initials: HF
authors.lastname: Chambers
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D024881:Drug Resistance, Bacterial; D006801:Humans; D012107:Research Design
chemical_list: D000900:Anti-Bacterial Agents